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In the cardiovascular system, the endothelial layer provides a natural antithrombogenic surface
on the inner portion of the heart and associated vessels. For a synthetic material therefore, the
ability to attract and retain endothelial or endothelial progenitor cells (EPCs), ultimately creating
a single endothelial layer on its surface, is of prime importance. The authors have developed a
nanocomposite polymer, based on a combination of polyhedral oligomeric silsesquioxane
nanoparticles and polycarbonate urea urethane (POSS-PCU), which is biocompatible and has
been used in human for the world’s first synthetic trachea, tear duct, and bypass graft. In this
study, the authors modified the surface of this casted nanocomposite by grafting fibronectin
derived bioactive peptides [glycine-arginine-glycine-aspartic acid-glycine (GRGDG) and lauric
acid conjugated GRGDG (GRGDG-LA)] to enhance the endothelialization for using heart valves
leaflets from circulating EPCs. Human peripheral blood mononuclear cells were separated using
Ficoll–Paque centrifugation, with harvested EPCs purified using CD34 microbead labeling and
magnetic-activated cell sorting. Cells were seeded onto 96 well plates coated with POSS-PCU,
GRGDG/GRGDG-LA modified POSS-PCU and PCU polymers, for a period of 21 days. Cells
were studied under light, confocal, and scanning electron microscope (SEM). Fluorescence-
activated cell sorting was used to analyze cell surface markers. Cell attachment and proliferation
was observed in all POSS-PCU samples, significantly higher than the activity seen within the
control PCU polymers (p< 0.05). Microscopic examination revealed clonal expansion and
morphological changes in cells seeded on POSS-PCU. The cells expressed increasing levels of
mature endothelial cell markers over time with a concurrent reduction in hematopoietic stem
cell marker expression. SEM showed a mixed population of morphologically differentiated
endothelial cells and EPCs. These results support the use of heart valve made with the
POSS-PCU polymer and demonstrate that suitable chemical modification of this nanocomposite
could increase self-endothelialization potential and reduce associated thrombotic events. VC 2016
American Vacuum Society. [http://dx.doi.org/10.1116/1.4939036]
I. INTRODUCTION
Heart valve prostheses, mechanical and bioprosthetic, are
among the most widely used biomedical devices. The need
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for these prostheses is rising due to the increasing incidence
of age related degenerative valve disease across both devel-
oped and developing nations.1 Although current mechanical
and bioprosthetic heart valves have been subject to consider-
able improvements over past decades, they are still prone to
a number of life-threatening complications. Mechanical
valves are inherently thrombogenic, resulting in patients’
spending lengthy periods on side-effect laden thrombolytic
medications, while bioprostheses display poor durability
over the human lifespan. These are problems which advance-
ments in modern science have not been able to rectify yet.2
Alternative options include synthetic leaflet heart valves and
tissue engineered cardiac valve prostheses, or a combination
of both in a hybrid prosthesis—the latter incidentally being
the focus of our research.
Despite the disappointing progress with the use of syn-
thetic polymeric materials in the experimental years of valve
replacement therapy, there has been renewed interest in the
application of newly emerged advanced materials in engi-
neering cardiovascular devices including synthetic leaflet
heart valves, bypass grafts, and stents. It is now thought that
synthetic leaflet heart valves based on enhanced polymeric
materials and advanced trileaflet valve designs can poten-
tially serve as a breakthrough in heart valve replacement
therapy.2
In the cardiovascular system, normal endothelial cell
function is crucial for all aspects of vascular homeostasis. In
particular, endothelial cells play an important role in the con-
tinuous adjustment of vascular tone, and hence the control of
blood pressure; in the physiological regulation of leukocyte
traffic from blood to tissues; and perhaps most importantly,
the maintenance of an antithrombotic and anticoagulant
balance in circulating blood. Utilization of this natural pro-
tective measure improves long-term survival of cardiovascu-
lar implants. This has been evidenced in studies where
bioprosthetic valve degeneration, calcification, and throm-
boembolic events have been reduced by surface coverage of
valves with autologous endothelial cells.3
Tissue engineering is a revolutionary methodology for the
generation of viable valve prostheses inherently capable of
repair and remodeling; both processes that current mechani-
cal and bioprosthetic heart valves do not undertake. In vivo
tissue engineering is an interesting concept, which utilizes
the natural regenerative capacity of the human body to create
partial or complete tissue engineering organ. Development
of innovative materials with smart surfaces to interact with
multipotent progenitor cells circulating in peripheral blood is
a key factor in this innovative approach. In particular, endo-
thelial progenitor cells (EPCs) are multipotent cells circulat-
ing in peripheral blood with natural regenerative capacity in
the cardiovascular system. They have preserved stemness
capacity with potential of proliferation and differentiation
into a variety of cell lines including endothelial cells.
Engineering bioresponsive smart polymers will enable these
autologous regenerative cells circulating in blood to recog-
nize and adhere to the polymer surface. This can be facili-
tated by various surface modification techniques to enhance
cell affinity and attachment. The main aim of these techni-
ques is to mimic extracellular matrix (ECM), which is a nat-
ural host for cells in the body.
Elements of ECM such as peptide sequences have been
suggested to affect cell response by directly interacting with
cell receptors, including recognition sequences derived from
laminin, IKLLI, and IKVAV;4 collagen type I derived
equence;5 and fibronectin derived sequences, RGD. RGD is
probably the most widely studied modification agent in poly-
meric cardiovascular implants in order to increase EC and
EPC adhesion.6,7 These cells can then proliferate and diffe-
rentiate into mature endothelial cells, eventually forming
a layer on the polymer surface.8 The potential of in situ
endothelialization could dramatically enhance blood compati-
bility and long-term durability of heart valves and other cardi-
ovascular implants, because it is now known that circulating
endothelial progenitor cells are inversely correlated with in-
stent restenosis in patients treated with EPC-capture stents.9
Our group has engineered a novel nanocomposite polymer
potentially suitable for this purpose. Polyhedral oligomeric
silsesquioxane–polycarbonate urea urethane (POSS-PCU) is
a novel nanocomposite based on POSS and PCU.
POSS (RSiO3/2)n due to a unique cagelike structure, nano-
scale dimensions (1.5 nm core), and the potential to tune
chemical interactions through multiple reactive functionalities
was an ideal candidate to incorporate into PCU and create
nanostructured hybrid material. Nanocomposite materials can
be produced by reacting POSS as a pendant group attached to
the polymer backbone, as an end-group, or as a cross-linking
agent in polymer matrix forming a reinforced network. In the
present study, reaction of the silanol (-SiOH) groups of
cyclohexanechlorohydrine-functionalized POSS with isocya-
nate gave segmented PCU with POSS incorporated as an end
group to the hard segment (Fig. 1). Therefore, POSS gives
rise to a linear organic–inorganic hybrid nanocomposite,
which reacts with a single (or double) polymerizable func-
tional group when grafted onto PCU forming covalent bonds.
Synthesized nanocomposite can offer unique structural prop-
erties compared to conventional microcomposites due to the
dispersion of nanoscale inorganic components in the poly-
meric matrix. POSS improves hemocompatibility of PCU due
to surface characteristics and more mobile surface moieties.
POSS-PCU nanocomposite has been demonstrated to
have antithrombogenic potential in conjunction with a
proven resistance to degradation.10 This novel polymer also
demonstrates excellent biocompatibility, biostability, and
advanced mechanical properties. Previous studies have also
indicated that POSS-PCU nanocomposite can sustain human
umbilical vein endothelial cell seeding.11,12 Our results have
also evidenced the anticalcification potential of this nano-
composite compared with other polyurethane polymers and
bioprosthetic tissues such as bovine pericardium, making
this nanocomposite a significant material of choice for engi-
neering synthetic leaflet heart valves. In this study, the abil-
ity of POSS-PCU nanocomposite to retain EPCs extracted
from human peripheral blood and umbilical cord blood was
assessed in vitro. Surface modified POSS-PCU using
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fibronectin derived sequences, glycine-arginine-glycine-
aspartic acid-glycine (GRGDG) and lauric acid conjugated
GRGDG (GRGDG-LA) were also assessed to investigate the
effect of these modifications on the cells’ behavior. In partic-
ular, the morphological changes, proliferation, and differen-
tiation capacity of seeded EPCs were monitored during the
culture period.
II. MATERIALS AND METHODS
A. Preparation of polymers
Synthesis of the POSS-PCU nanocomposite has been
described in detail previously.13 In brief, the inorganic ure-
thane is made from 4,40-methylene-bis(phenylisocyanate)
(MDI), poly(hexamethylene carbonate) diol, and silses-
quioxane dissolved in tetrahydrofuran, here, bis[3-(trime-
thoxysilyl)propyl]amine, and a chain extended with
ethylene diamine in N,N0-dimethylacetamide. 1-butanol
dimethylacetamide was added to form a 20% (w/v) solution
of POSS-PCU with the POSS moiety, therein being at a
concentration of 2%. All chemicals were purchased from
Aldrich Limited (Gillingham, UK).
PCU polymer was synthesized using commercial methods
as follows: Dry polycarbonate polyol (2000 mwt) was placed
in a 250 ml reaction flask equipped with a mechanical stirrer
and nitrogen inlet. The polyol was heated to 60 C, and then,
flake MDI was added and reacted with the polyol, under
nitrogen, at 70–80 C for 90 min to form a prepolymer. Dry
dimethylacetamide was added slowly to the prepolymer to
form a solution; the solution was cooled to 40 C. Chain
extension of the prepolymer was carried out by the dropwise
addition of a mixture of ethylenediamine and diethylamine
in dry dimethylacetamide. After completion of the chain
extension, 1-butanol in dimethylacetamide was added to the
polymer solution. In this study, PCU was used as a control.
Using 18% POSS-PCU and PCU polymers, films of nano-
composite were casted with a thickness of 100 lm, which is
the thickness of the proposed heart valve leaflets.14 The
FIG. 1. Simplified reaction scheme of nanocomposite synthesis.
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resulting films were then thoroughly washed with sterile
phosphate-buffered saline (PBS) and were sterilized by
immersion in 70% ethanol followed by air-drying.
B. Synthesis of GRGDG and LA-GRGDG
The synthesis of a 5-residue peptide Gly-Arg-Gly-Asp-
Gly-hexanoic-COOH was carried out manually by a step-
wise solid phase method on a Rink acid resin in which
0.15 mmol of hydroxyl groups are present. The Rink resin
was washed with dimethylformamide (DMF; 10 ml/g; 5
1 min). A solution of Fmoc-Gly (1 mmol) in dichlorome-
thane (DCM; 5 ml) was stirred at room temperature and acti-
vated by adding diisopropylcarbodiimide in dry DCM to the
amino acid solution. The mixture was stirred for 15 min at
0 C, and then, 5 ml of DMF was added. The mixture was
then added to the Rink acid resin. Dimethylaminopyridine
was dissolved in DCM (0.1 eq. relative to resin loading) and
then was added to the resin/amino acid mixture. The mixture
was agitated for 1 h with oxygen free nitrogen gas.
Sequential addition of the protected amino acids was carried
out to complete sequence. The Rink-acid solid phase was
finally treated with 95% trifluoroacetic acid to completely
detach and deprotect the peptide from the solid phase. The
final product was precipitated using cold diethylether. The
peptide was purified by HPLC using a semipreparative C16
column. In the case of LA-GRGDG, the same process was
followed by the conjugation of LA prior to the detachment
of the peptide. Rink-amide resin and F-moc amino acids
were supplied by Novabiochem, Beeston, UK, and all other
chemicals by Rathburn, Walkerburn, Scotland.
C. Biofunctionalization of the POSS-PCU surface with
peptides
Cast films of POSS-PCU nanocomposite were used to
graft GRGDG and GRGDG-LA using a modified direct
grafting method.15 Three different concentrations (1, 2, and
10 mg/g of polymer) of GRGDG and GRGDG-LA peptides
were prepared and coated onto polymer films in a clean
fume cupboard and air dried. Once dried, the samples were
exposed to 2% (v/v) glutaraldehyde in PBS solution and
incubated for 2 h. The samples were washed with PBS three
times and were rinsed with water containing 0.1% Triton
X-100, then with water, and stored dry until further use.
D. Characterization of the surfaces
The samples of modified and nonmodified polymers were
characterized using atomic force microscopy (AFM) and atte-
nuated total reflectance Fourier transform infrared (ATR-
FTIR). The surface morphology was investigated using AFM
in a semicontact mode using a Nanoscope III multimode
scanning probe microscope (Digital Instruments, Veeco
Instruments, Inc., New York). The AFM micrographs of the
surfaces were collected over a scan area of 100 100lm for
all samples. At least four randomly selected areas of each
sample were analyzed for surface roughness values. ATR-
FTIR spectra of the polymers were obtained using a Nicolet
8700 FTIR spectrometer (Thermo Electron Corporation,
UK), in conjunction with an ATR accessory at room tempera-
ture. Data were collected on germanium crystal using a
variable-angle ATR unit at a nominal incident angle of 45.
The samples were cut randomly from polymer films, cut to
ATR crystal size, and mounted on trapezoid crystal. Spectra
were recorded in the midinfrared region (4000–400 cm1) at
4 cm1 resolution and averaging 128 numbers of scans. The
spectra data were acquired using OMNIC 7.2 software.
E. Contact angle measurement
The contact angle is a measure of the ability of a liquid
to spread on a solid surface. Water contact angle provides
information on the affinity of water to a solid surface, or
hydrophilicity and hydrophobicity of the material in other
words. Measurements of static water contact angle were
taken according to the standard procedure. In brief, a small
drop of deionized water (20 ll) was put onto the flat sample
surfaces using a syringe such that the drop volume at the sur-
face expands. The resulting contact angle was evaluated by
optical methods using a digital camera. The measurements
were taken in an air-conditioned laboratory at 25 C. For
each sample, the measurement was repeated six times.
F. Isolation of EPC from peripheral and umbilical cord
blood
With consent from healthy volunteers, fresh whole
blood (50 ml) was obtained using a Vacutainer system (BD
Bioscience), containing preservative free heparin. With con-
sent, human umbilical cord blood was collected from placen-
tal cord of volunteers undergoing cesarean section delivery
immediately after delivery of placenta to avoid clot forma-
tion. Peripheral blood mononuclear cells were isolated by
Ficoll-Paque (GE Health care Bio-science, Sweden) density
gradient centrifugation (400 g, 40 min at 20 C) and resus-
pended in PBS containing 2 mM EDTA (autoMACS Rinsing
Solution, Miltenyi Biotec, Germany). The cells were washed
three times and resuspended into 300 ll autoMACS buffer
for magnetic labeling. To block nonspecific/specific binding
via fragment crystallisable region (FcR), 100 ll of FcR
blocking human IgG was added followed by adding the
same amount of MicroBeads conjugated with antihuman
CD34 antibodies (CD34 MicroBead kit, Militenyi Biotec,
UK). The cell suspension was incubated in the fridge for 30
min at 4 C and then loaded onto a magnetic-activated cell
sorting (MACS) column, which was placed in the magnetic
field of MACS separator. The magnetically retained
CD34þcells were collected and washed.
G. Evaluation of EPC purity
The purity of the isolated CD34þ cells was evaluated by
flowcytometry. Following magnetic separation, the labeled
cells were stained with monoclonal anti-CD34-PerCPCy5.5
(BD Bio-Science), anti-CD133-APC (Miltenyi Biotec
GmbH), anti-VEGFR2-FITC, and anti-CD144-PE (R&D
Systems) at 4 C for 15 min. After additional washing, the
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cells were fixed in 4% paraformaldehyde and immediately
sorted using a florescence-activated cell sorting (FACS)
Calibur flowcytometer in conjunction with CELL QUEST soft-
ware. A minimum of 10 000 cells were acquired for each
analyzed sample.
H. EPC culture
Isolated EPCs were seeded onto 96-well plates coated
with POSS-PCU nanocomposite and GRGDG & lauric acid
conjugated GRGDG modified POSS-PCU and PCU polymer
as a control. A separate control was EPC culture in a petri
dish. Endothelial cell growth medium (Provitro GmbH,
Germany) was used supplemented with fetal calf serum
10%, heparin 22.50lg, epidermal growth factor (EGF)
05.00 ng, basic fibroblast growth factor (bFGF) 10.00 ng,
vascular endothelial growth factor (VEGF) 00.50 ng, argi-
nine 3-insulin like growth factor-1 (R3-IGF-1) 20.00 ng,
ascorbic acid 01.00lg, hydrocortisone 00.20 lg, gentamicin
50.00 lg, and amphothericin B 50.00 ng (Provitro GmbH,
Germany). The medium was changed weekly during the
21-day period.
I. EPC characterization
Immunostaining for cell surface markers was carried out
on day 1, 7, 14, and 21 on different samples. The cells were
collected from individual wells and stained for the surface
markers, including CD34 PerCyP, VEGFR2 FITC, CD144
PE, CD133 APC, CD31 APC, and VW FITC. Surface stain-
ing was carried out at 4 C for 15 min. The cells were then
washed with PBS, resuspended in 100 ll of 4% paraformal-
dehyde, and were sorted using FACS Calibur system. The
FLOWJO software (Tree Star, Inc., USA) was used for combi-
nation analysis of different subsets. Morphological studies
were carried out using live light microscopy, scanning elec-
tron microscopy, and confocal microscopy.
J. Measurement of cell metabolism
Cell metabolism was assessed by Alamar blueTM (AB)
(Serotec, Kidlington, UK) assay at day 1, 7, 14, and 21 as
described in literature.12 In brief, the medium was removed
from the polymer film-coated dishes, and 4 ml of 10% AB in
cell culture medium (CCM) was added. After 4-h incubation,
the samples of AB/CCM were removed and measured on a
Fluroskan Ascent FL (Thermo Labsystems, Basingstoke,
UK) fluorescent plate reader (excitation 530 nm, emission at
620 nm). The unseeded polymer film-coated petri dishes
were used as controls.
K. Statistical analysis
GRAPHPAD PRISM (version 5) was used for plotting graphs
and for statistical analysis, Student’s t test and two-way
ANOVAs were used as indicated.
III. RESULTS
A. Surface characterization
The AFM results (Fig. 2) revealed that incorporation
of POSS to PCU led to an increase in the roughness values
for POSS-PCU (96.836 3.2 nm) compared to PCU (49.7
6 2.4 nm). The surface morphology and topography was dra-
matically changed by the inclusion of POSS into PCU,
resulting in a specific micro-/nanoglobular texture of POSS-
PCU. Surface modification of POSS-PCU films with
GRGDG and GRGDG-LA peptides significantly increased
the surface roughness (181.26 4.6, 185.346 3.7 nm, succes-
sively), indicating the effect of peptide grafting on the
surface topography.
Further assessment of the surfaces was carried out using
ATR-FTIR (Fig. 3). The results showed that surface modifi-
cation with GRGDG and GRGDG-LA (fixing reaction) has
created new chemistry on the surface. The IR peak at
1100 cm1 confirmed the existence of Si-O-Si groups in the
silsesquioxane cages on surface of all modified POSS-PCU
films. Although the POSS related peaks appeared to be
unchanged, the peaks at 1742 cm1 correspond to C¼O
group on the surface of PCU and POSS-PCU disappeared
due to GRGDG and GRGDG-LA deposition. Moreover,
urethane amide groups at 1635, 1532, and 1253 cm1 were
affected in GRGDG and GRGDG-LA fixing process. This
confirms that amide groups in both GRGDG and GRGDG-
LA modified polymers were involved in cross-linking reac-
tion (fixing process). It is also evident that the C-N group in
POSS modified films at 1230 cm1 did not change due
to peptide deposition. Surface characterization results
confirm the presence of peptide sequences in the modified
polymers.
B. Contact angle measurement
Water contact angle measures the hydrophobicity/
hydrophilicity of a material. Incorporation of POSS to
PCU increases water contact angle and surface hydropho-
bicity. POSS-PCU displayed a contact angle of 115 (65),
suggesting a certain degree of hydrophobicity (Fig. 4).
After conjugation with peptides, POSS-PCU displayed
a reduced hydrophobicity, shown by a reduction in the
contact angle to 87 (66) and 84 (67), for GRGDG and
GRGDG-LA, respectively. The effect of water contact
angle on hemocompatibility is still not clearly defined, but
peptide grafting certainly changes the water contact angle
of the material.
C. Isolation of EPC
Isolated peripheral blood mononuclear cells and CD34þ
labeled cells were counted by two independent observers
after each cell extraction. The number of isolated mononu-
clear cells was 760.06 105.8 103/ml for peripheral blood
samples obtained from healthy adult volunteers while it
was 16106 187.4 103/ml in the samples extracted from
umbilical cord blood, which was significantly higher
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(p< 0.05) compared to peripheral blood. After extracting
CD34þ cells using magnetic activated cell sorting method,
the number of labeled cells extracted from peripheral
blood (18.136 1.92 103/ml) was significantly lower
than the one for isolated from umbilical cord blood
(31.426 2.02 103/ml) (p< 0.05, n: 3).
D. Evaluation of EPC purity
In order to evaluate the purity of the labeled cells for
the expression of CD34 surface marker, the samples of la-
beled and unlabeled cell population were stained with anti-
CD34 FITC and acquired by FACS Calibur. In each set of
the experiments, high levels of purification for CD34þ
FIG. 2. AFM images of (a) PCU, (b) POSS-PCU, (c) GRGDG modified POSS-PCU, and (d) GRGDG-LA modified POSS-PCU (X, Y, Z ¼ 100
 100 1.5 lm). The surface morphology and roughness were dramatically changed by surface modifying agents compared to the unmodified
PCU.
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cells were found using FACS immunostaining, as shown in
Fig. 5.
E. EPC proliferation
The isolated peripheral blood mononuclear cells and
CD34þ labeled cells were counted by two independent
observers after each cell extraction. The number of isolated
mononuclear cells was 760.06 105.8 103/ml for periph-
eral blood samples obtained from healthy adult volunteers
while it was 16106 187.4 103/ml in the samples extracted
from umbilical cord blood, which was significantly higher
(p< 0.05) compared to peripheral blood. After extracting
CD34þ cells using magnetic activated cell sorting method,
the number of labeled cells extracted from peripheral blood
(18.136 1.92 103/ml) was significantly lower than the one
for isolated from umbilical cord blood (31.426 2.02 103/
ml) (p< 0.05, n: 3).
F. EPC differentiation
The isolated CD34þ cells were seeded on the 96-well
plates coated with POSS-PCU, PCU, GRGDG-LA, and
GRGDG modified POSS-PCU nanocomposite and cultured
for 21 days. During the culture, the cells were monitored for
morphological changes, the presence of EPC colony forming
units, and the overall cell population and proliferation capa-
bility of the cells. Representative live microscopy images of
the arrangement of colony forming units on days 7 and 14
are shown in Fig. 6. The colonies were defined morphologi-
cally as a central core of round cells with elongated cells at
the periphery.16,17 Confocal microscopy of the colonies
revealed that the majority of the cells forming the colonies
were positive for CD34 surface marker, as shown in Fig. 7.
To confirm the identity of the cultured cells, the cells were
studied by FACS for surface markers. In particular, ran-
domly selected samples of the cells cultured on different
polymer disks were collected and stained with antibodies
directed to CD34, CD133, VEGFR2, and CD144, and
acquired using FACS Calibur flowcytometer on days 1, 7,
14, and 21. Using the appropriate gating system, the fre-
quency of a specific subset of cells, which were positive for
CD34, CD133, and VEGFR2, was determined. This subset is
considered as true EPC in literature.18 As shown in Fig. 8,
the frequency of triple positive cells (positive for CD34,
CD133, and VEGFR2), which are considered as true EPC,
was increased over time, thus showing the expansion of this
cell subset within the colonies. The GRGDG-LA modified
POSS-PCU retained higher percentage of EPC compared to
FIG. 3. ATR-FTIR spectra of PCU, POSS-PCU, and GRGDG and GRGDG-LA modified POSS-PCU used in the experiment, in the range of 2000–700 cm1.
Induced changes in the surface spectra are the results of surface modification. The Si-C, Si-O-Si, Si-H, and CH bonds of the POSS nanocages revealed peaks
at 1230, 1100, 834, and 738 cm1, respectively, on all POSS-PCU polymers. Peaks at 1742 cm1 correspond to C¼O group and at 1635, 1532, and 1253 cm1
representing urethane amide groups were affected in GRGDG and GRGDG-LA modification.
FIG. 4. Contact angle measurement results of PCU, POSS-PCU, POSS-PCU
GRGDG, and POSS-PCU GRGDG LA samples. The water contact angle
results show that the POSS incorporation significantly increased hydropho-
bicity of the surface of PCU, whereas peptide grafting renders the surface
less hydrophobic. Data are presented as mean6 SEM.
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the other polymers, as shown in Fig. 8, indicating that this
novel functionalized nanocomposite polymer may offer bet-
ter in situ endothelialization of heart valves.
G. EPC differentiation
Over the time of culture, cells changed morphologically
from spindle-shape characteristic for early EPCs to cobble
stone, indicating potential differentiation of the cells to
mature endothelial cells [Figs. 6(c) and 6(d)]. FACS analysis
confirmed the increase in the expression of endothelial spe-
cific cell surface markers, including VEGFR2, CD144,
CD31, and von Willebrand factor (Figs. 9–11). FACS analy-
sis revealed that the cells cultured on different polymer disk
expressed CD144 with the increase in time. The cells iso-
lated from adult human peripheral blood expressed this
marker more frequently than the cells separated from umbili-
cal cord blood. Since CD144 is a mature endothelial cell
marker, it can be concluded that umbilical cord EPCs remain
undifferentiated for longer than adult peripheral blood coun-
terparts. Higher percentage of triple positive EPCs in cord
blood samples is also in accordance with this finding.
Similar results were found for VEGFR2 surface marker
expression during the culture period (Fig. 11). Higher
expression of VEGFR2 at day 7 on cells extracted from pe-
ripheral blood compared to the ones isolated from umbilical
cord blood indicates more stemness feature of EPCs
originated from umbilical cord. However, EPCs from both
sources could differentiate into endothelial cells cultured on
all polymer surfaces after three weeks culture. Cultured cells
were further analyzed for the expression of other endothelial
cell surface markers, including CD31 and von Willebrand
factor. The results showed that these markers were also
highly expressed by the cultured cells after one week, as
shown in Fig. 10. This again confirms differentiation of the
cells into mature endothelial cells. In order to determine the
expression of endothelial specific cell surface markers, the
cultured cells were stained for von Willebrand factor and
VEGFR2 at day 14 (Fig. 12). The results revealed that the
cells were positive for these markers, indicating the presence
of endothelial cells on the samples.
SEM of the samples taken at day 7 revealed adequate cell
attachments on the POSS-PCU samples morphologically
similar to endothelial cells (flat, spindle-shaped cells with
numerous filopodia) (Fig. 13).
H. Cell metabolism
Cell metabolism was measured using Alamar Blue
VR
, a
vital dye which viable cells metabolize from blue (resazurin)
to pink (resorufin), and the change in color was detected
spectroscopically.19 The cells remained highly viable during
the experiment, and there was no significant reduction in cell
metabolism in the samples during the culture compared to
FIG. 5. Representative FACS plots of the labeled cells (top row) and unlabeled cells (bottom row) isolated using CD34 microbeads, showing high degree of pu-
rification achieved after separation by MACS.
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FIG. 7. (a) Representative image of EPC colonies at day 14, and (b) the confocal microscopy image of the same colony shows expression of CD34 surface
markers on the colony forming cells.
FIG. 6. Live microscopy images of the isolated cells cultured on POSS-PCU nanocomposite samples. Colonies of EPC (marked with arrows) undergoing pro-
liferation resulted in an increased cell population over time of culture as shown on day 7 (a) and day 14 (b). The cells underwent morphological changes during
the culture and spindle-shaped morphology of early EPCs on day 7 (a) was dominated by cobble stone-shaped confluent layer at day 21 (c), characteristic mor-
phology of the endothelial cells. (d) Higher magnification of confluent layer of EC on day 21.
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metabolism measured by Alamar Blue assay at day 1, as
shown in Table I.
IV. DISCUSSION
Studies have shown that progenitor stem cells circulating
in the blood have regenerative capacity and play a role in the
natural reconstruction and remodeling process of cardiovas-
cular system. It has been demonstrated20 that bone marrow
derived hematopoietic progenitor cells can give rise to ECs
and contribute to endothelial recovery and new capillary for-
mation after ischemia. These cells provide a reparative
capacity for cardiovascular system by contribution in repair
as well as the growth of new blood vessels. Potentially, this
capacity can be used in re-endothelialization of the decellu-
larized matrix or synthetic implants.21 Several lines of evi-
dence point to an important role of EPC in revascularization
process in an adult, but the exact definition of EPC still
remains a controversy. Different surface markers have been
used to characterize EPCs, and based on that, various isola-
tion techniques have been used to extract these cells from
peripheral blood. We used the most commonly accepted sur-
face markers, i.e., CD34, CD133, and VEGFR2, as represen-
tative markers of true EPCs. The frequency of the cells
being positive for these three markers was very low in the
peripheral blood samples compared to those in the umbilical
cord blood samples. However, in both cases, there was a sig-
nificant increase in the frequency of triple positive EPCs,
showing that this subset has been the subject to proliferation
and expansion over the time of culture. The increase was
higher in umbilical cord blood samples, and EPCs extracted
from adult peripheral blood differentiated to ECs earlier than
the ones extracted from cord blood, confirming higher stem-
ness characteristics of these cells reported in other studies.22
However, clinically peripheral blood sample results may be
more relevant, and the aim of further work will be to
increase endothelial cell coverage on used nanopolymers. As
stimulation of EPC colony formation could be a double-
edged sword because it can increase the risk of clotting and
unwanted differentiation of EPCs into smooth muscle cells
FIG. 8. Frequency of triple positive EPC (positive for CD34, CD133, and
VEGFR2) on different samples over the time of experiment. (a) The cells
extracted from peripheral blood (PB) and (b) cells isolated from umbilical
cord blood (UCB). As shown, there was a significant increase in the fre-
quency of this subset of cells at day 21 compared to day 1 on POSS-PCU
and GRGDG-LA modified samples (two way ANOVA; *p < 0.05; **p <
0.01, and ***p < 0.001). UCB, umbilical cord blood; PB, peripheral blood;
GRGDG, POSS-PCU modified with GRGDG peptide; GRGDG-LA, POSS-
PCU modified with lauric acid conjugated GRGDG peptide; (numbers
within brackets), concentration of peptide as mg/g polymer.
FIG. 9. Expression of CD144 (endothelial cell surface markers) on cells cul-
tured on different polymer disks. The cells isolated from peripheral blood
(a) differentiated more rapidly (at day 7), compared to the cells extracted
from umbilical cord blood (b). As shown, there was a significant increase in
the expression of CD144 on most of the samples compared to day 1 (two
way ANOVA; *p < 0.05 and **p < 0.01, and ***p < 0.001).
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may exacerbate intimal hyperplasia,23 care must be taken to
ensure EPCs differentiate into ECs. POSS-PCU nanocompo-
site and the GRGDG-LA modified nanocomposite revealed
higher levels of EPC expansion compared to the PCU and
GRGDG modified polymers (p< 0.05). The surface compo-
sition and its chemical and physical properties are determin-
ing factors in the cell affinity of a synthetic surface. We
assume that the presence of POSS in nanocomposite surface
promotes EPC proliferation by providing favorable environ-
ment in terms of surface topography and biochemical prop-
erties. It has been already shown that the POSS modification
affects the nanotopography of the surface as well as hydro-
phobicity24 and cell affinity,12 although the exact mechanism
is not completely known and is currently under investigation.
Also, the GRGDG-LA modified polymers showed higher
degree of EPC expansion, which was in accordance with pre-
vious findings.6,7 It is clear from ATR-FTIR and AFM
results that both POSS modification and peptide grafting
have changed the surface chemistry and its texture topogra-
phy. These might be the reasons behind enhanced cell
attachment and proliferation in surface modified samples
compared with the unmodified PCU sample.
Previous cardiovascular implants developed in our labo-
ratories using POSS-PCU, including vascular grafts tested
in vivo and currently in clinical trials,25 have been developed
using coagulation technique, left in a water-bath to allow
phase-separation to occur and resulted in spongylike con-
structs, which posses elastic and pulsatile properties of blood
vessels. We have also shown that with the increase in pore
size in POSS-PCU, there is a reduction in tensile strain and
strength.26 In this study, POSS-PCU was fabricated using
casting technique, which renders it mechanical strength and
solid structure suitable for cardiac valves. This design would
produce valves with optimized hemodynamic features and
reduced stress distribution over the leaflets.
In order to facilitate cell attachment to the synthetic sur-
face, various peptide sequences derived from ECM have
been isolated and grafted onto materials to enhance
(a)
(b)
FIG. 10. Expression of VEGFR2 (an endothelial cell surface marker) on the
cultured cells; Like CD144, the cells isolated from peripheral blood (a)
expressed differentiation markers more rapidly (on day 7) compared to the
cells extracted from umbilical cord blood (b). As shown, there was a signifi-
cant increase in the expression of CD 144 on most of the samples compared
to day 1 (two way ANOVA; *p < 0.05 and **p < 0.01, and ***p < 0.001).
FIG. 11. Representative FACS plots of the cultured cells on POSS-PCU sample at day 7, indicating positive expression of CD31 and vWF by the cultured cells.
Population of CD34þ cells (a) were analyzed for the expression of CD31 (b) and vWF (c), showing that endothelial cell surface markers were highly expressed
by the cultured cells.
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FIG. 12. Immunostaining results of the cultured cells on day 14; samples of the cultured cells were stained for vWF (a) and VEGFR2 (b), showing positive
expression of these surface markers on the cells.
FIG. 13. Scanning electron microscopy of the cells cultured on: (a) PCU sample and (b) POSS-PCU samples. Colonies of the cells (marked with arrows) were
observed by SEM at day 7, strongly attached to the polymer surface.
TABLE I. Cell metabolism determined by Alamar BlueTM assay measuring fluorescence (excitation: 530; emission: 620). Data are presented as mean 6 SEM
(n: 3).
Time
samples Day 1 Day 7 Day 14 Day 21
Control 61.126 2.69 55.016 8.42 101.026 1.83 73.886 9.71
PCU 73.516 7.40 50.126 3.1 80.186 7.64 67.166 11.38
POSS-PCU 73.636 4.65 60.076 7.57 92.416 2.57 81.306 12.6
GRGDG-LA (1) 81.866 10.73 52.136 7.75 79.926 13.46 62.396 2.66
GRGDG-LA (2) 72.276 2.92 67.426 14.50 92.206 3.84 62.736 2.54
GRGD-LA (10) 73.786 8.11 56.426 6.75 91.796 4.34 60.226 7.75
GRGDG (1) 78.816 13.54 58.636 7.38 81.046 2.51 50.196 8.26
GRGDG (2) 80.246 7.70 60.426 4.79 96.566 6.54 50.66 6.47
GRGDG (10) 69.276 15.51 63.616 10.48 99.236 3.91 60.266 5.02
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biological properties and influence cell behavior. Examples
are REDV,27 PHSRN,28 RGD,29 GRGDG, and GRGDSP
from fibronectin;30 stem cell homing factor SDF-1a;31,32 and
collagen type I derived sequence, laminin-derived recogni-
tion sequences, IKLLI, IKVAV;33 DGEA.4 Of the peptides
investigated, the RGD peptide has featured in the largest
number of biomaterials studies.34 In cardiovascular bioen-
gineering, biofunctionalization of polycarbonate polyur-
ethane urea, and nanocomposite polymers with RGD/
modified RGD and heparin, has been reported to increase
EC and EPC adhesion.6,7,35–37
In this study, we used a sequence of Gly-Arg-Gly-Asp-Gly
(GRGDG) peptide and GRGDG conjugated with lauric acid
GRGDG-LA to modify the surface of nanocomposite in order
to improve cell affinity of the surface. Lauric acid conjugation
was used to facilitate incorporation of the peptide into the ma-
trix of the polymer and has been shown to be suitable to
enhance cell metabolism on the modified surfaces.7 Different
concentrations of the peptides (1, 2, and 10 mg/g of polymer)
were used in order to assess their effect on cell attachment,
proliferation, and differentiation. Microscopic observation
revealed higher population of the cells on the POSS-PCU
nanocomposite and the GRGDG-LA modified nanocompo-
sites. FACS analysis showed that the frequency of triple posi-
tive EPCs in the POSS-PCU and GRGDG-LA modified
polymers (concentrations of 2 and 10 mg/g) was significantly
higher at day 21 compared to day 1 in both the peripheral
blood and umbilical cord blood samples. Interestingly, the
expression of CD144 and VEGFR2 was also significantly
higher for the same polymers (POSS-PCU and GRGDG-LA,
2 and 10 mg/g) at day 21 compared to day 1 in the umbilical
cord blood samples. However, in peripheral blood series, they
were high in all samples regardless of the type of the polymer.
According to the results, we assume that the GRGDG-LA
modification was better than the GRGDG modification and
POSS-PCU itself, and provides preferred environment for
EPC proliferation and differentiation. The cells remained
highly viable during the culture, and there was no significant
change over the time and between the samples compared to
day 1, even though there was some fluctuation in Alamar
Blue assay results.
The POSS-PCU nanocomposite has been shown to have
antithrombogenic potential, improved biocompatibility, and
calcification resistance, but in order to achieve optimal endo-
thelialization of cardiovascular implants and form antithrom-
botic and anti-platelet barrier, novel techniques of coating
POSS-PCU to maximize EPC capture must be developed.
One possibility to increase EPC capture is by covalent bind-
ing of antibodies against EPC cell-specific biomarkers to
cardiovascular implants.38 In vivo study of pulmonary valves
conjugated with antibodies against CD133 showed no
evidence of calcification and thrombi formation three months
postimplantation into sheep model.39 Preliminary in vitro
studies in our laboratory with POSS-PCU nanocomposite
polymer functionalized with antibodies against CD133
showed minimal increase in EPCs capture,40 but significant
improvement in endothelialization and hemocompatibility
was observed with immobilized anti-CD34 antibodies on
POSS-PCU.41 Nevertheless, the use of antibodies carries
drawbacks: it involves delicate chemical conjugation and
more complex manufacturing process. Also, it poses a new
challenge to maintain the viability of the antibody in order to
have a long shelf life. Thus, this approach would increase the
cost of the implant, making it less likely to find large-scale
clinical application. Therefore, several issues need to be
addressed in order to find optimal surface covering of cardio-
vascular implants, and in this study, we tested a different set
of peptides. Our results suggest that the POSS-PCU nano-
composite could be modified by GRGDG-LA and used in the
development of new generation synthetic leaflet heart valves
with in situ endothelialization potential by attracting endothe-
lial progenitor stem cells from circulating blood. However,
more experiments are required to test hemocompatibility
in vitro42 before commencing in vivo testing. For further
evaluation, the next step is dynamic EPCs culture on heart
valve prototypes in a specifically developed bioreactor
system.
V. CONCLUSIONS
In an in vitro setting, EPCs were extracted from adult
peripheral blood and umbilical cord blood and cultured on
the POSS-PCU nanocomposite in comparison with PCU,
GRGDG, and GRGDG-LA modified polymers. EPCs’
proliferation and differentiation was noticed over the time
of culture. The POSS-PCU nanocomposite revealed an
enhanced cell affinity and capability to provide a cell
friendly environment for EPC proliferation and differentia-
tion. According to the results, this nanocomposite material
can be used for the development of synthetic leaflet heart
valves, but modification with suitable peptides could result
in superior in-situ endothelialization capability.
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